Jian Hong1, Budong Chen2, Xin Yao2, Yushan Yang2. 1. Department of Neurosurgery, Tianjin HuanHu Hospital, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin Neurosurgical Institute, Jinnan District, Tianjin, China. Electronic address: hongjian80000@163.com. 2. Department of Neurosurgery, Tianjin HuanHu Hospital, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin Neurosurgical Institute, Jinnan District, Tianjin, China.
Abstract
PURPOSE: To compare surgical outcomes and adverse events between patients received microsurgical resection of high-grade gliomas with or without fluorescein sodium-guidance. PATIENTS: A retrospective study was conducted in our hospital between June 2016 and January 2017. Patients were divided into 2 groups: Fluorescein Group (42 patients) and Nonfluorescein Group (40 patients). MEASUREMENTS: Intraoperative (hemorrhage value and operation time) and postoperative (consistency between fluorescence-stained tissue and histopathological results, rate of resection) measurements were documented. Postoperative adverse events were recorded. Patients were followed up for 6 months to evaluate postsurgery glioma recurrence. MAIN RESULTS: Intraoperatively, hemorrhage value, and operation time were significantly less in Fluorescencein than in Nonfluorescencein group. The rate of glioma complete resection was significantly higher in Fluorescencein than in Nonfluorescencein group (85.7%vs 62.5%, P = 0.02). The rate of glioma recurrence was significantly lower in Fluorescencein than in Nonfluorescencein group (11.9%vs 25.0%, P = 0.01), and no significant differences on adverse events were observed. CONCLUSIONS: Intraoperative fluorescein sodium-guidance could facilitate the complete resection and significantly decrease the postoperative recurrence in patients with high-grade gliomas.
PURPOSE: To compare surgical outcomes and adverse events between patients received microsurgical resection of high-grade gliomas with or without fluorescein sodium-guidance. PATIENTS: A retrospective study was conducted in our hospital between June 2016 and January 2017. Patients were divided into 2 groups: Fluorescein Group (42 patients) and Nonfluorescein Group (40 patients). MEASUREMENTS: Intraoperative (hemorrhage value and operation time) and postoperative (consistency between fluorescence-stained tissue and histopathological results, rate of resection) measurements were documented. Postoperative adverse events were recorded. Patients were followed up for 6 months to evaluate postsurgery glioma recurrence. MAIN RESULTS: Intraoperatively, hemorrhage value, and operation time were significantly less in Fluorescencein than in Nonfluorescencein group. The rate of glioma complete resection was significantly higher in Fluorescencein than in Nonfluorescencein group (85.7%vs 62.5%, P = 0.02). The rate of glioma recurrence was significantly lower in Fluorescencein than in Nonfluorescencein group (11.9%vs 25.0%, P = 0.01), and no significant differences on adverse events were observed. CONCLUSIONS: Intraoperative fluorescein sodium-guidance could facilitate the complete resection and significantly decrease the postoperative recurrence in patients with high-grade gliomas.
Authors: Pietro Zeppa; Raffaele De Marco; Matteo Monticelli; Armando Massara; Andrea Bianconi; Giuseppe Di Perna; Stefania Greco Crasto; Fabio Cofano; Antonio Melcarne; Michele Maria Lanotte; Diego Garbossa Journal: Brain Sci Date: 2022-04-26
Authors: Walter Stummer; Raphael Koch; Ricardo Diez Valle; David W Roberts; Nadar Sanai; Steve Kalkanis; Constantinos G Hadjipanayis; Eric Suero Molina Journal: Acta Neurochir (Wien) Date: 2019-07-30 Impact factor: 2.216
Authors: Lasse Cramer Ahrens; Mathias Green Krabbenhøft; Rasmus Würgler Hansen; Nikola Mikic; Christian Bonde Pedersen; Frantz Rom Poulsen; Anders Rosendal Korshoej Journal: Cancers (Basel) Date: 2022-01-26 Impact factor: 6.639
Authors: Evgenii Belykh; Naomi R Onaka; Xiaochun Zhao; Irakliy Abramov; Jennifer M Eschbacher; Peter Nakaji; Mark C Preul Journal: Front Neurol Date: 2021-07-16 Impact factor: 4.003